Ergocalciferol - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (1)Enzymes (5)

Targets (1)Enzymes (5)Biointeractions (6)

Identification

Name

Ergocalciferol

Accession Number

DB00153 (NUTR00005, APRD00426)

Type

Small Molecule

Groups

Approved, Nutraceutical

Description

Ergocalciferol (Vitamin D2) is a derivative of ergosterol formed by ultraviolet rays breaking of the C9-C10 bond. It differs from cholecalciferol in having a double bond between C22 and C23 and a methyl group at C24.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

(3β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol

(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol

(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol

Activated ergosterol

Ercalciol

Ergocalciférol

Ergocalciferol

Ergocalciferolum

Oleovitamin D2

Viosterol

Vitamin D2

Vitamina D2

External IDs

Not Available

Product Ingredients

Not Available

Product Images

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
D-forte	Capsule	50000 unit	Oral	Sandoz Canada Incorporated	1999-12-30	Not applicable	Canada
D-forte	Capsule	50000 unit	Oral	Euro Pharm International Canada Inc	Not applicable	Not applicable	Canada
Drisdol	Capsule, liquid filled	1.25 mg/1	Oral	Sanofi Aventis	1974-11-11	Not applicable	US
Drisdol	Capsule, liquid filled	1.25 mg/1	Oral	Avera Mc Kennan Hospital	2016-02-05	Not applicable	US
Drisdol	Capsule, liquid filled	1.25 mg/1	Oral	Validus Pharmaceuticals	1974-01-11	Not applicable	US
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	Winthrop U.S.	2009-11-10	Not applicable	US
Osto-D2	Capsule	50000 unit	Oral	Paladin Labs Inc	2008-02-08	Not applicable	Canada
Radiostol Cap 50000iu	Capsule	50000 unit	Oral	Allen & Hanburys A Glaxo Canada Ltd. Co.	1989-12-15	1996-09-10	Canada

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Ergocalciferol	Capsule	1.25 mg/1	Oral	Golden State Medical Supply	2009-08-17	Not applicable	US
Ergocalciferol	Capsule	1.25 mg/1	Oral	Blenheim Pharmacal, Inc.	2013-10-02	Not applicable	US
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	Unit Dose Services	2010-07-23	Not applicable	US
Ergocalciferol	Capsule	1.25 mg/1	Oral	bryant ranch prepack	2009-08-17	Not applicable	US
Ergocalciferol	Capsule	1.25 mg/1	Oral	St. Marys Medical Park Pharmacy	2014-05-22	Not applicable	US
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	Rising Pharmaceuticals	2010-07-23	Not applicable	US
Ergocalciferol	Capsule	1.25 mg/1	Oral	Breckenridge Pharmaceutical, Inc.	2009-08-17	Not applicable	US
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	Clinical Solutions Wholsesale	2010-07-23	2017-06-24	US
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	Av Kare, Inc.	2012-06-05	2016-02-04	US
Ergocalciferol	Capsule	1.25 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2009-08-17	Not applicable	US
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	Carilion Materials Management	2010-07-23	Not applicable	US
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	Proficient Rx LP	2010-07-23	Not applicable	US
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2016-06-15	Not applicable	US
Ergocalciferol	Capsule	1.25 mg/1	Oral	Aidarex Pharmaceuticals LLC	2009-08-17	Not applicable	US
Ergocalciferol	Capsule	1.25 mg/1	Oral	Kaiser Foundations Hospitals	2016-04-26	Not applicable	US
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	Bionpharma Inc.	2016-06-15	Not applicable	US
Ergocalciferol	Capsule	1.25 mg/1	Oral	Dispensing Solutions, Inc.	2009-08-17	Not applicable	US
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	Sigma Pharm Laboratories, Llc	2012-01-28	Not applicable	US
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	Banner Life Sciences Llc.	2015-06-01	Not applicable	US
Ergocalciferol	Capsule	1.25 mg/1	Oral	Pliva, Inc.	2002-06-01	Not applicable	US
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	Remedy Repack	2017-01-25	Not applicable	US
Ergocalciferol	Capsule	1.25 mg/1	Oral	Physicians Total Care, Inc.	2007-07-12	Not applicable	US
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2016-06-15	Not applicable	US
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	Ready Meds	2010-07-23	Not applicable	US
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	Av Kare, Inc.	2015-07-23	Not applicable	US
Ergocalciferol	Capsule	1.25 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2009-08-17	Not applicable	US
Ergocalciferol	Capsule	1.25 mg/1	Oral	A S Medication Solutions	2009-08-17	2017-06-20	US
Ergocalciferol	Capsule	1.25 mg/1	Oral	Amerincan Health Packaging	2011-01-07	Not applicable	US
Vitamin D	Capsule, liquid filled	1.25 mg/1	Oral	Paddock Laboratories, Inc.	2009-12-15	2015-11-30	US
Vitamin D	Capsule	1.25 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2015-02-23	Not applicable	US
Vitamin D	Capsule	1.25 mg/1	Oral	Sun Pharmaceutical Industries Limited	2010-03-15	Not applicable	US
Vitamin D	Capsule	1.25 mg/1	Oral	A S Medication Solutions	2010-03-15	2017-06-20	US
Vitamin D	Capsule	1.25 1/1	Oral	Avera Mc Kennan Hospital	2015-03-13	Not applicable	US
Vitamin D	Capsule	1.25 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2010-03-15	Not applicable	US
Vitamin D	Capsule	1.25 mg/1	Oral	bryant ranch prepack	2010-03-15	Not applicable	US
Vitamin D	Capsule	1.25 1/1	Oral	Proficient Rx LP	2014-05-16	Not applicable	US
Vitamin D	Capsule	1.25 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-04-12	Not applicable	US
Vitamin D	Capsule	1.25 mg/1	Oral	A S Medication Solutions	2010-03-15	2017-06-20	US
Vitamin D	Capsule	1.25 1/1	Oral	Remedy Repack	2016-02-09	Not applicable	US
Vitamin D	Capsule	1.25 1/1	Oral	Strides Shasun Limited	2014-05-16	Not applicable	US
Vitamin D	Capsule	1.25 mg/1	Oral	Aidarex Pharmaceuticals LLC	2014-05-16	Not applicable	US
Vitamin D	Capsule	1.25 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2010-03-15	Not applicable	US
Vitamin D	Capsule	1.25 1/1	Oral	Preferreed Pharmaceuticals Inc.	2016-06-08	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Calcidol	Not Available
Deltalin	Not Available

Brand mixtures

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Aquasol A & D Drops	Ergocalciferol Vitamin A	Solution / drops	Oral	Rhone Poulenc Rorer	1993-12-31	1996-09-09	Canada
Cal/mag 2:1 With D	Calcium Ergocalciferol Magnesium	Tablet	Oral	Wn Pharmaceuticals Ltd.	1998-06-26	2000-02-02	Canada
Calcium Mg and Zn Capsules With Vitamin D	Calcium Ergocalciferol Magnesium Zinc	Capsule	Oral	Rheingold Food International Ltd.	1995-12-31	2007-07-26	Canada
Calcium Chelate Plus Vit D	Calcium Ergocalciferol	Tablet	Oral	Hall Laboratories, Ltd.	1981-12-31	2003-09-11	Canada
Calcium Citrate W Vitamin D Tab	Calcium Citrate Ergocalciferol	Tablet	Oral	Nutri Dyn Products Ltd.	1994-12-31	1996-09-09	Canada
Calcium Magnesium 2:1 Tablets With Vitamin D	Calcium Ergocalciferol Magnesium	Tablet	Oral	Sisu Inc.	2004-01-30	2009-08-04	Canada
Calcium Magnesium Avec Vitamine D Et Zinc	Calcium Ergocalciferol Magnesium oxide Zinc gluconate	Tablet	Oral	Les Aliments Nutri Source Inc.	1991-12-31	1996-09-09	Canada
Calcium Magnesium Plus Vitamin D Liquid	Calcium gluconate Ergocalciferol Inositol nicotinate Magnesium citrate	Liquid	Oral	Jamp Pharma Corporation	2002-04-22	2003-02-05	Canada
Calcium With Vitamin D2	Calcium Ergocalciferol	Capsule	Oral	Sisu Inc.	2002-12-18	2008-07-25	Canada
Calcium With Vitamins C and D Tab	Calcium Ergocalciferol Vitamin C	Tablet	Oral	Pure Life International Prods Inc.	1993-12-31	2000-07-27	Canada
Children Pediatric Vitamins Drops	Ergocalciferol Vitamin A Vitamin C	Solution / drops	Oral	Stanley Pharmaceuticals, A Division Of Vita Health Products Inc.	1990-12-31	2002-07-31	Canada
Childrens Chewable Multiple Vitamins Tab	Cyanocobalamin Ergocalciferol Folic Acid Nicotinamide Pyridoxine Riboflavin Thiamine Vitamin A Vitamin C Vitamin E	Tablet	Oral	Pharmavite	1987-12-31	2000-08-24	Canada
Formula Cm	Choline Ergocalciferol Inositol nicotinate L-Methionine Magnesium Nicotinamide Pantothenic acid Pyridoxine	Tablet	Oral	Nutrivention Nutritional Products	Not applicable	Not applicable	Canada
Formula EC	Calcium Copper Ergocalciferol Magnesium Magnesium silicate Manganese Pyridoxine Zinc	Tablet	Oral	Body Wise International Llc	Not applicable	Not applicable	Canada
Formula Js	Ergocalciferol Magnesium Nicotinamide Pantothenic acid Potassium Pyridoxine	Tablet	Oral	Nutrivention Nutritional Products	Not applicable	Not applicable	Canada
Infant's Multiple Vitamin Drops	Ergocalciferol Vitamin A Vitamin C	Liquid	Oral	Stanley Pharmaceuticals, A Division Of Vita Health Products Inc.	1991-12-31	2002-07-31	Canada
Infants' Vitamin Drops	Ergocalciferol Vitamin A Vitamin C	Solution / drops	Oral	Ksl Pharmaceuticals	1991-12-31	1998-08-13	Canada
Insur-all Vitamin Supplement	Biotin Choline Cyanocobalamin Ergocalciferol Inositol nicotinate Nicotinamide Pantothenic acid Pyridoxine Riboflavin Thiamine Vitamin A Vitamin C Vitamin E	Tablet	Oral	Garden State Nutritionals	1998-10-16	2000-06-07	Canada
Kanga-V Multivitamins & Minerals	Biotin Calcium Chromium Copper Cyanocobalamin Ergocalciferol Folic Acid Iron Magnesium Manganese Nicotinamide Pantothenic acid Potassium Iodide Pyridoxine Riboflavin Thiamine Vitamin C Vitamin E Zinc	Tablet, effervescent	Oral	Lacombe Drugs (1992) Ltd	Not applicable	Not applicable	Canada
Kenwood Liquid Supplement	Ergocalciferol Manganese Nicotinamide Pantothenic acid Potassium Pyridoxine Riboflavin Thiamine Vitamin A Vitamin C	Liquid	Oral	Kenwood Laboratories (Division Of Bradley Pharmaceuticals)	Not applicable	Not applicable	Canada
M.V.I. Pediatric	Biotin Cyanocobalamin Dexpanthenol Ergocalciferol Folic Acid Nicotinamide Phylloquinone Pyridoxine Riboflavin Thiamine Vitamin A Vitamin C Vitamin E	Injection, powder, lyophilized, for solution	Intravenous	Hospira Worldwide, Inc.	1983-04-06	Not applicable	US
Maxi 10 Tab	Cyanocobalamin Ergocalciferol Folic Acid Nicotinamide Pantothenic acid Pyridoxine Riboflavin Thiamine Vitamin A Vitamin C Vitamin E	Tablet	Oral	Desbergers LtÉe, Division Of Technilab Inc.	1979-12-31	1999-09-17	Canada
Maxi 6 Liq	Ergocalciferol Nicotinamide Riboflavin Thiamine Vitamin A Vitamin C	Liquid	Oral	Desbergers LtÉe, Division Of Technilab Inc.	1980-12-31	1999-09-17	Canada
Multiple Vitamin Plus Minerals Tab	Calcium Copper Cyanocobalamin Ergocalciferol Iron Nicotinamide Pantothenic acid Potassium Iodide Pyridoxine Riboflavin Thiamine Vitamin A Vitamin C	Tablet	Oral	Hall Laboratories, Ltd.	1981-12-31	2003-09-11	Canada
Multiple Vitamins	Cyanocobalamin Ergocalciferol Folic Acid Nicotinamide Pyridoxine Riboflavin Thiamine Vitamin A Vitamin C Vitamin E	Tablet	Oral	Stanley Pharmaceuticals, A Division Of Vita Health Products Inc.	1987-12-31	2002-07-31	Canada
Multiple Vitamins With Iron	Cyanocobalamin Ergocalciferol Folic Acid Iron Nicotinamide Pyridoxine Riboflavin Thiamine Vitamin A Vitamin C Vitamin E	Tablet	Oral	Stanley Pharmaceuticals, A Division Of Vita Health Products Inc.	1987-12-31	2002-07-31	Canada
Onccor	Beta carotene Biotin Choline Chromium Cupric oxide Cyanocobalamin Ergocalciferol Folic Acid Inositol nicotinate Manganese Molybdenum Nicotinamide Pantothenic acid Potassium Potassium Iodide Pyridoxine Riboflavin Selenium Thiamine Vitamin A Vitamin C Vitamin E Zinc	Tablet	Oral	Simone Protective Pharmaceuticals, Inc.	Not applicable	Not applicable	Canada
One A Day Tab	Biotin Calcium Choline Copper Cyanocobalamin Ergocalciferol Folic Acid Inositol nicotinate Iodine Iron Magnesium Manganese Nicotinamide Pantothenic acid Potassium Pyridoxine Riboflavin Thiamine Vitamin A Vitamin C Vitamin E Zinc	Tablet	Oral	Country Health Laboratories Ltd.	1982-12-31	2001-07-27	Canada
Paramettes Syrup	Cyanocobalamin Ergocalciferol Iron Nicotinamide Pyridoxine Riboflavin Thiamine Vitamin A Vitamin C	Syrup	Oral	Wyeth Ayerst Canada Inc.	1994-12-31	2002-07-31	Canada
Sopalamine/3b Plus C	Cyanocobalamin Ergocalciferol Folic Acid Nicotinamide Pantothenic acid Pyridoxine Riboflavin Thiamine Vitamin A Vitamin C Vitamin E	Tablet	Oral	Technilab Pharma Inc.	1987-12-31	2001-09-05	Canada
Tender Age Multi Vitamins	Ergocalciferol Nicotinamide Riboflavin Thiamine Vitamin A Vitamin C	Liquid	Oral	Jamieson Laboratories Ltd	1982-12-31	2000-09-08	Canada
Vitamines Pour Bebes Et Enfants	Ergocalciferol Nicotinamide Pyridoxine Riboflavin Thiamine Vitamin A Vitamin C	Liquid	Oral	Herbes Universelles Inc.	1978-12-31	2009-07-15	Canada
Zoo Chews	Cyanocobalamin Ergocalciferol Folic Acid Nicotinamide Pyridoxine Riboflavin Thiamine Vitamin A Vitamin C Vitamin C Vitamin E	Tablet	Oral	Hall Laboratories, Ltd.	1981-12-31	2003-09-11	Canada

Categories

UNII

VS041H42XC

CAS number

50-14-6

Weight

Average: 396.6484
Monoisotopic: 396.33921603

Chemical Formula

C₂₈H₄₄O

InChI Key

MECHNRXZTMCUDQ-RKHKHRCZSA-N

InChI

InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1

IUPAC Name

(1S,3Z)-3-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexan-1-ol

SMILES

CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C

Pharmacology

Indication

For use in the management of hypocalcemia and its clinical manifestations in patients with hypoparathyroidism, as well as for the treatment of familial hypophosphatemia (vitamin D resistant rickets). This drug has also been used in the treatment of nutritional rickets or osteomalacia, vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis).

Structured Indications

Pharmacodynamics

Ergoalcifediol (Vitamin D2) is a fat soluble steroid hormone precursor of vitamin D. The principal biologic function of vitamin D is the maintenance of normal levels of serum calcium and phosphorus in the bloodstream by enhancing the efficacy of the small intestine to absorb these minerals from the diet. Cholecalciferol is synthesized within our bodies naturally, but if UV exposure is inadequate or the metabolism of cholecalciferol is abnormal, then an exogenous source is required. Vitamin D2 is converted to 25-hydroxyvitamin D (25OHD) in the liver, and then to the active form, 1,25-dihydroxyvitamin D (1,25(OH)2D), in the kidney. Once transformed, it binds to the vitamin D receptor, which leads to a variety of regulatory roles. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma. Very few foods naturally contain vitamin D. Sources that contain the vitamin include fatty fish, the liver and fat of aquatic mammals (e.g., seals, polar bears), and eggs from chickens fed vitamin D-fortified feed. As such, many countries have instituted policies to fortify certain foods with vitamin D to compensate for the potentially low exposures of skin to sunlight. Vitamin D deficiency results in inadequate mineralization of bone or compensatory skeletal demineralization and causes decreased ionized calcium concentrations in blood and a resultant increase in the production and secretion of PTH. Increase in PTH stimulates the mobilization of skeletal calcium, inhibits renal excretion of calcium, and stimulates renal excretion of phosphorus. This results in normal fasting serum calcium concentrations and low or near-normal serum phosphorus. The enhanced mobilization of skeletal calcium induced by this secondary hyperparathyroidism leads porotic bone.

Mechanism of action

Activated ergocalciferol increases serum calcium and phosphate concentrations, primarily by increasing intestinal absorption of calcium and phosphate through binding to a specific receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein. 25-hydroxyergocalciferol is the intermediary metabolite of ergocalciferol. Although this metabolite exhibits 2–5 times more activity than unactivated ergocalciferol in curing rickets and inducing calcium absorption and mobilization (from bone) in animals, this increased activity is still insufficient to affect these functions at physiologic concentrations. Activated ergocalciferol stimulate resorption of bone and are required for normal mineralization of bone. Physiological doses of ergocalciferol also promotes calcium reabsorption by the kidneys, but the significance of this effect is not known.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Vitamin D3 receptor	Protein	yes	agonist	Human	P11473	details

Absorption

Readily absorbed from small intestine (proximal or distal), requires presence of bile salts.

Volume of distribution

Not Available

Protein binding

>99.8%

Metabolism

Within the liver, ergocalciferol is hydroxylated to ercalcidiol (25-hydroxyergocalciferol) by the enzyme 25-hydroxylase. Within the kidney, ercalcidiol serves as a substrate for 1-alpha-hydroxylase, yielding ercalcitriol (1,25-dihydroxyergocalciferol), the biologically active form of vitamin D2.

Substrate	Enzymes	Product
Ergocalciferol	Not Available	25-Hydroxyvitamin D2-25-glucuronide	Details
Ergocalciferol	Not Available	Vitamin D2 3-glucuronide	Details
Ergocalciferol	Not Available	25-Hydroxyvitamin D2 25-(beta-glucuronide)	Details

Route of elimination

Not Available

Half life

19 to 48 hours (however, stored in fat deposits in body for prolonged periods).

Clearance

Not Available

Toxicity

LD₅₀ = 23.7 mg/kg (Orally in mice); LD₅₀ = 10 mg/kg (Orally in rats ); Nausea, vomiting and diarrhea, weight loss, irritability, weakness, fatigue, lassitude, and headache.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
Acetyldigitoxin	Ergocalciferol may increase the arrhythmogenic activities of Acetyldigitoxin.	Approved
Alfacalcidol	The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Alfacalcidol.	Approved, Nutraceutical
Aluminum hydroxide	The serum concentration of Aluminum hydroxide can be increased when it is combined with Ergocalciferol.	Approved
Amiodarone	The metabolism of Ergocalciferol can be decreased when combined with Amiodarone.	Approved, Investigational
Aprepitant	The serum concentration of Ergocalciferol can be increased when it is combined with Aprepitant.	Approved, Investigational
Atazanavir	The metabolism of Ergocalciferol can be decreased when combined with Atazanavir.	Approved, Investigational
Atomoxetine	The metabolism of Ergocalciferol can be decreased when combined with Atomoxetine.	Approved
Bendroflumethiazide	Bendroflumethiazide may increase the hypercalcemic activities of Ergocalciferol.	Approved
Bexarotene	The serum concentration of Ergocalciferol can be decreased when it is combined with Bexarotene.	Approved, Investigational
Boceprevir	The metabolism of Ergocalciferol can be decreased when combined with Boceprevir.	Withdrawn
Bortezomib	The metabolism of Ergocalciferol can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Ergocalciferol can be decreased when it is combined with Bosentan.	Approved, Investigational
Calcidiol	The risk or severity of adverse effects can be increased when Calcidiol is combined with Ergocalciferol.	Approved, Nutraceutical
Calcipotriol	The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Calcipotriol.	Approved
Calcitriol	The risk or severity of adverse effects can be increased when Calcitriol is combined with Ergocalciferol.	Approved, Nutraceutical
Calcium	The risk or severity of adverse effects can be increased when Calcium is combined with Ergocalciferol.	Nutraceutical
Calcium Acetate	The risk or severity of adverse effects can be increased when Calcium Acetate is combined with Ergocalciferol.	Approved
Calcium Carbonate	The risk or severity of adverse effects can be increased when Calcium carbonate is combined with Ergocalciferol.	Approved
Calcium Chloride	The risk or severity of adverse effects can be increased when Calcium Chloride is combined with Ergocalciferol.	Approved
Calcium Citrate	The risk or severity of adverse effects can be increased when Calcium citrate is combined with Ergocalciferol.	Approved
Calcium glubionate	The risk or severity of adverse effects can be increased when Calcium glubionate is combined with Ergocalciferol.	Approved
Calcium Gluceptate	The risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Ergocalciferol.	Approved
Calcium gluconate	The risk or severity of adverse effects can be increased when Calcium gluconate is combined with Ergocalciferol.	Approved, Vet Approved
Carbamazepine	The metabolism of Ergocalciferol can be increased when combined with Carbamazepine.	Approved, Investigational
Ceritinib	The serum concentration of Ergocalciferol can be increased when it is combined with Ceritinib.	Approved
Chlorothiazide	Chlorothiazide may increase the hypercalcemic activities of Ergocalciferol.	Approved, Vet Approved
Chlorthalidone	Chlorthalidone may increase the hypercalcemic activities of Ergocalciferol.	Approved
Cholecalciferol	The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Cholecalciferol.	Approved, Nutraceutical
Cholestyramine	The serum concentration of Ergocalciferol can be decreased when it is combined with Cholestyramine.	Approved
Clarithromycin	The metabolism of Ergocalciferol can be decreased when combined with Clarithromycin.	Approved
Clemastine	The metabolism of Ergocalciferol can be decreased when combined with Clemastine.	Approved
Clotrimazole	The metabolism of Ergocalciferol can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Cobicistat	The metabolism of Ergocalciferol can be decreased when combined with Cobicistat.	Approved
Colesevelam	The serum concentration of Ergocalciferol can be decreased when it is combined with Colesevelam.	Approved
Colestipol	The serum concentration of Ergocalciferol can be decreased when it is combined with Colestipol.	Approved
Conivaptan	The serum concentration of Ergocalciferol can be increased when it is combined with Conivaptan.	Approved, Investigational
Crizotinib	The metabolism of Ergocalciferol can be decreased when combined with Crizotinib.	Approved
Cyclosporine	The metabolism of Ergocalciferol can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Dabrafenib	The serum concentration of Ergocalciferol can be decreased when it is combined with Dabrafenib.	Approved
Danazol	Danazol may increase the hypercalcemic activities of Ergocalciferol.	Approved
Darunavir	The metabolism of Ergocalciferol can be decreased when combined with Darunavir.	Approved
Dasatinib	The serum concentration of Ergocalciferol can be increased when it is combined with Dasatinib.	Approved, Investigational
Deferasirox	The serum concentration of Ergocalciferol can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The metabolism of Ergocalciferol can be decreased when combined with Delavirdine.	Approved
Deslanoside	Ergocalciferol may increase the arrhythmogenic activities of Deslanoside.	Approved
Dexamethasone	The serum concentration of Ergocalciferol can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Digitoxin	Ergocalciferol may increase the arrhythmogenic activities of Digitoxin.	Approved
Digoxin	Ergocalciferol may increase the arrhythmogenic activities of Digoxin.	Approved
Dihydroergotamine	The metabolism of Ergocalciferol can be decreased when combined with Dihydroergotamine.	Approved
Dihydrotachysterol	The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Dihydrotachysterol.	Approved
Diltiazem	The metabolism of Ergocalciferol can be decreased when combined with Diltiazem.	Approved
Doxercalciferol	The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Doxercalciferol.	Approved
Doxycycline	The metabolism of Ergocalciferol can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronedarone	The metabolism of Ergocalciferol can be decreased when combined with Dronedarone.	Approved
Efavirenz	The serum concentration of Ergocalciferol can be decreased when it is combined with Efavirenz.	Approved, Investigational
Enzalutamide	The serum concentration of Ergocalciferol can be decreased when it is combined with Enzalutamide.	Approved
Erythromycin	The metabolism of Ergocalciferol can be decreased when combined with Erythromycin.	Approved, Vet Approved
Eslicarbazepine acetate	The serum concentration of Ergocalciferol can be decreased when it is combined with Eslicarbazepine acetate.	Approved
Etravirine	The serum concentration of Ergocalciferol can be decreased when it is combined with Etravirine.	Approved
Fluconazole	The metabolism of Ergocalciferol can be decreased when combined with Fluconazole.	Approved
Fluvoxamine	The metabolism of Ergocalciferol can be decreased when combined with Fluvoxamine.	Approved, Investigational
Fosamprenavir	The metabolism of Ergocalciferol can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Ergocalciferol can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The metabolism of Ergocalciferol can be increased when combined with Fosphenytoin.	Approved
Fusidic Acid	The serum concentration of Ergocalciferol can be increased when it is combined with Fusidic Acid.	Approved
Hydrochlorothiazide	Hydrochlorothiazide may increase the hypercalcemic activities of Ergocalciferol.	Approved, Vet Approved
Hydroflumethiazide	Hydroflumethiazide may increase the hypercalcemic activities of Ergocalciferol.	Approved
Idelalisib	The serum concentration of Ergocalciferol can be increased when it is combined with Idelalisib.	Approved
Imatinib	The metabolism of Ergocalciferol can be decreased when combined with Imatinib.	Approved
Indapamide	Indapamide may increase the hypercalcemic activities of Ergocalciferol.	Approved
Indinavir	The metabolism of Ergocalciferol can be decreased when combined with Indinavir.	Approved
Isavuconazonium	The metabolism of Ergocalciferol can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isradipine	The metabolism of Ergocalciferol can be decreased when combined with Isradipine.	Approved
Itraconazole	The metabolism of Ergocalciferol can be decreased when combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Ergocalciferol can be increased when it is combined with Ivacaftor.	Approved
Ketoconazole	The metabolism of Ergocalciferol can be decreased when combined with Ketoconazole.	Approved, Investigational
Lopinavir	The metabolism of Ergocalciferol can be decreased when combined with Lopinavir.	Approved
Lovastatin	The metabolism of Ergocalciferol can be decreased when combined with Lovastatin.	Approved, Investigational
Luliconazole	The serum concentration of Ergocalciferol can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The metabolism of Ergocalciferol can be increased when combined with Lumacaftor.	Approved
Methyclothiazide	Methyclothiazide may increase the hypercalcemic activities of Ergocalciferol.	Approved
Metolazone	Metolazone may increase the hypercalcemic activities of Ergocalciferol.	Approved
Mifepristone	The serum concentration of Ergocalciferol can be increased when it is combined with Mifepristone.	Approved, Investigational
Mitotane	The serum concentration of Ergocalciferol can be decreased when it is combined with Mitotane.	Approved
Modafinil	The serum concentration of Ergocalciferol can be decreased when it is combined with Modafinil.	Approved, Investigational
Nafcillin	The serum concentration of Ergocalciferol can be decreased when it is combined with Nafcillin.	Approved
Nefazodone	The metabolism of Ergocalciferol can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The metabolism of Ergocalciferol can be decreased when combined with Nelfinavir.	Approved
Netupitant	The serum concentration of Ergocalciferol can be increased when it is combined with Netupitant.	Approved
Nevirapine	The metabolism of Ergocalciferol can be increased when combined with Nevirapine.	Approved
Nilotinib	The metabolism of Ergocalciferol can be decreased when combined with Nilotinib.	Approved, Investigational
Olaparib	The metabolism of Ergocalciferol can be decreased when combined with Olaparib.	Approved
Oleandrin	Ergocalciferol may increase the arrhythmogenic activities of Anvirzel.	Experimental
Orlistat	The serum concentration of Ergocalciferol can be decreased when it is combined with Orlistat.	Approved, Investigational
Osimertinib	The serum concentration of Ergocalciferol can be increased when it is combined with Osimertinib.	Approved
Ouabain	Ergocalciferol may increase the arrhythmogenic activities of Ouabain.	Approved
Palbociclib	The serum concentration of Ergocalciferol can be increased when it is combined with Palbociclib.	Approved
Paricalcitol	The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Paricalcitol.	Approved, Investigational
Pentobarbital	The metabolism of Ergocalciferol can be increased when combined with Pentobarbital.	Approved, Vet Approved
Phenobarbital	The metabolism of Ergocalciferol can be increased when combined with Phenobarbital.	Approved
Phenytoin	The metabolism of Ergocalciferol can be increased when combined with Phenytoin.	Approved, Vet Approved
Polythiazide	Polythiazide may increase the hypercalcemic activities of Ergocalciferol.	Approved
Posaconazole	The metabolism of Ergocalciferol can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Primidone	The metabolism of Ergocalciferol can be increased when combined with Primidone.	Approved, Vet Approved
Quinethazone	Quinethazone may increase the hypercalcemic activities of Ergocalciferol.	Approved
Ranolazine	The metabolism of Ergocalciferol can be decreased when combined with Ranolazine.	Approved, Investigational
Rifabutin	The metabolism of Ergocalciferol can be increased when combined with Rifabutin.	Approved
Rifampicin	The metabolism of Ergocalciferol can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Ergocalciferol can be increased when combined with Rifapentine.	Approved
Ritonavir	The metabolism of Ergocalciferol can be decreased when combined with Ritonavir.	Approved, Investigational
Saquinavir	The metabolism of Ergocalciferol can be decreased when combined with Saquinavir.	Approved, Investigational
Sildenafil	The metabolism of Ergocalciferol can be decreased when combined with Sildenafil.	Approved, Investigational
Siltuximab	The serum concentration of Ergocalciferol can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The serum concentration of Ergocalciferol can be increased when it is combined with Simeprevir.	Approved
St. John's Wort	The serum concentration of Ergocalciferol can be decreased when it is combined with St. John's Wort.	Nutraceutical
Stiripentol	The serum concentration of Ergocalciferol can be increased when it is combined with Stiripentol.	Approved
Sucralfate	The serum concentration of Sucralfate can be increased when it is combined with Ergocalciferol.	Approved
Sulfisoxazole	The metabolism of Ergocalciferol can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Telaprevir	The metabolism of Ergocalciferol can be decreased when combined with Telaprevir.	Withdrawn
Telithromycin	The metabolism of Ergocalciferol can be decreased when combined with Telithromycin.	Approved
Ticlopidine	The metabolism of Ergocalciferol can be decreased when combined with Ticlopidine.	Approved
Tocilizumab	The serum concentration of Ergocalciferol can be decreased when it is combined with Tocilizumab.	Approved
Trichlormethiazide	Trichlormethiazide may increase the hypercalcemic activities of Ergocalciferol.	Approved, Vet Approved
Venlafaxine	The metabolism of Ergocalciferol can be decreased when combined with Venlafaxine.	Approved
Verapamil	The metabolism of Ergocalciferol can be decreased when combined with Verapamil.	Approved
Voriconazole	The metabolism of Ergocalciferol can be decreased when combined with Voriconazole.	Approved, Investigational
Ziprasidone	The metabolism of Ergocalciferol can be decreased when combined with Ziprasidone.	Approved

Food Interactions

Not Available

References

Synthesis Reference

Charles W. Bishop, Glenville Jones, Ronald L. Horst, Nicholas J. Koszewski, Joyce C. Knutson, Raju Penmasta, Robert M. Moriarty, Stephen Strugnell, Timothy A. Reinhardt, Liang Guo, Sanjay K. Singhal, Lei Zhao, "Methods for preparation and use of 1A,24(S)-dihydroxy vitamin D2." U.S. Patent US5789397, issued March, 1992.

US5789397

General References

DeLuca HF: Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1689S-96S. [PubMed:15585789 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB00900
KEGG Drug	D00187
KEGG Compound	C05441
PubChem Compound	5280793
PubChem Substance	46505053
ChemSpider	4444351
ChEBI	28934
ChEMBL	CHEMBL1536
Therapeutic Targets Database	DAP000291
PharmGKB	PA449484
HET	D2V
Drug Product Database	4924
RxList	http://www.rxlist.com/cgi/generic/ergocalciferol.htm
Drugs.com	http://www.drugs.com/cdi/ergocalciferol.html
PDRhealth	http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/vit_0265.shtml
Wikipedia	Ergocalciferol

ATC Codes

A11CC01 — Ergocalciferol

AHFS Codes

Not Available

PDB Entries

Not Available

FDA label

Not Available

MSDS

Download (78.4 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Active Not Recruiting	Prevention	Deficiency, Vitamin D	1
0	Completed	Supportive Care	Neoplasms, Breast	1
0	Completed	Treatment	Chronic Kidney Disease (CKD)	1
1	Active Not Recruiting	Diagnostic	Hyperparathyroidism	1
1	Active Not Recruiting	Treatment	Diabetes, Diabetes Mellitus Type 1	1
1	Active Not Recruiting	Treatment	Peyronie's Disease	1
1	Completed	Basic Science	Insulin Sensitivity	1
1	Completed	Diagnostic	Bone destruction	1
1	Completed	Health Services Research	Deficiency, Vitamin D	1
1	Completed	Prevention	Gastrointestinal Cancers / Hypertensive / Prostate Cancer	1
1	Completed	Prevention	Physiological Effects of Vitamin D	1
1	Completed	Treatment	Inflammatory Reaction / Insulin Resistance	1
1	Completed	Treatment	Sarcopenia / Strength, Muscle	1
1	Completed	Treatment	Solid Cancers	1
1	Completed	Treatment	Type 2 Diabetes Mellitus	1
1	Recruiting	Treatment	Adult Women / Estrogen Receptor Positive / Metastatic Breast Cancer (MBC)	1
1	Recruiting	Treatment	Sarcopenia	1
1	Suspended	Not Available	Hepatocellular,Carcinoma / Liver Cirrhosis	1
1	Unknown Status	Treatment	Asthma Bronchial	1
1, 2	Completed	Prevention	Biomarker Change Linked to Breast Cancer	1
1, 2	Completed	Prevention	Cancer, Breast	1
1, 2	Completed	Treatment	Colorectal Cancers	1
1, 2	Completed	Treatment	Sickle Cell Disorders	1
1, 2	Not Yet Recruiting	Treatment	Deficiency, Vitamin D / Orthopedic Disorders / Polytrauma	1
1, 2	Terminated	Treatment	Bone Diseases / Cancer, Breast	1
1, 2	Withdrawn	Treatment	Ulcerative Colitis (UC)	1
2	Active Not Recruiting	Treatment	Diabetes, Diabetes Mellitus Type 1	2
2	Completed	Not Available	Deficiency, Vitamin D / HIV Disease / Human Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections	1
2	Completed	Prevention	Respiratory Tract Infections (RTI) / Vitamin D	1
2	Completed	Treatment	Allergic Rhinoconjunctivitis	1
2	Completed	Treatment	Cancer, Breast	2
2	Completed	Treatment	Chronic Heart Failure (CHF)	1
2	Completed	Treatment	Chronic Hepatitis C Virus (HCV) Infection	1
2	Completed	Treatment	Deficiency, Vitamin D	1
2	Completed	Treatment	Early Stage Breast Cancer	1
2	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	2
2	Completed	Treatment	Pulmonary Tuberculosis (TB)	1
2	Completed	Treatment	Type 2 Diabetes Mellitus	1
2	Completed	Treatment	Bone destruction	1
2	Not Yet Recruiting	Prevention	Deficiency, Vitamin D / Hypertensive	1
2	Not Yet Recruiting	Prevention	Neurofibromatosis Type 1 (NF1)	1
2	Not Yet Recruiting	Treatment	Deficiency, Vitamin D / Neurocognitive Dysfunction	1
2	Recruiting	Prevention	Bone destruction / Osteopenia	1
2	Recruiting	Treatment	Acute Myeloid Leukaemias (AML)	1
2	Recruiting	Treatment	Bone Metabolism / Hyperparathyroidism, Primary	1
2	Recruiting	Treatment	Cancer, Breast	1
2	Recruiting	Treatment	Cervical Cancers / Endometrial Cancers / Uterine Cancers	1
2	Recruiting	Treatment	Polycystic Ovarian Syndrome	1
2	Recruiting	Treatment	Bone destruction / Rheumatoid Arthritis	1
2	Recruiting	Treatment	Bone destruction	1
2	Terminated	Prevention	D Vitamin Deficiency Patients	1
2	Unknown Status	Prevention	Cancer, Breast	1
2	Unknown Status	Prevention	Sickle Cell Disorders	1
2	Unknown Status	Treatment	Advanced Intrahepatic Cholangiocarcinoma	1
2	Unknown Status	Treatment	Deficiency, Vitamin D / Hepatitis C Infection	1
2	Unknown Status	Treatment	Hypovitaminosis D / Type 2 Diabetes Mellitus	1
2	Unknown Status	Treatment	Insulin Resistance	1
2	Unknown Status	Treatment	Optic Neuritis	1
2	Unknown Status	Treatment	Peritoneal dialysis therapy	1
2	Withdrawn	Treatment	Asthma Bronchial	1
2, 3	Completed	Prevention	Impaired Glucose Tolerance (IGT)	1
2, 3	Completed	Treatment	Deficiency, Vitamin D / Hypercalcemia / Hyperparathyroidism, Primary	1
2, 3	Not Yet Recruiting	Treatment	Allergic Bronchopulmonary Aspergilloses	1
2, 3	Not Yet Recruiting	Treatment	Restless Legs Syndrome (RLS)	1
2, 3	Recruiting	Treatment	Allergies	1
2, 3	Recruiting	Treatment	Diabetes, Diabetes Mellitus Type 1	1
2, 3	Unknown Status	Treatment	Crohns Disease	1
2, 3	Withdrawn	Treatment	Calcium Nephrolithiasis / Deficiency, Vitamin D	1
3	Active Not Recruiting	Prevention	Heart Failure, Unspecified	1
3	Active Not Recruiting	Prevention	Vitamin D Status During Pregnancy	1
3	Active Not Recruiting	Treatment	Cutaneous Malignant Melanoma	1
3	Completed	Health Services Research	Deficiency, Vitamin D	1
3	Completed	Health Services Research	Diabetes, Diabetes Mellitus Type 1	1
3	Completed	Prevention	Bone destruction / Bone Diseases / Cardiovascular Disease (CVD) / Colonic Neoplasms / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia / Neoplasms, Breast / One to five years postmenopausal	1
3	Completed	Prevention	Migraine According to International Headache Society (IHS) Criteria (ICHD-II)	1
3	Completed	Prevention	Bone destruction	1
3	Completed	Treatment	Alzheimer's Disease (AD)	1
3	Completed	Treatment	Chronic Kidney Disease Stage 3 and 4	1
3	Completed	Treatment	Chronic Renal Insufficiency / Proteinuria	1
3	Completed	Treatment	Deficiency, Vitamin D	1
3	Completed	Treatment	Deficiency, Vitamin D / Heart Failure, Unspecified	1
3	Completed	Treatment	Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)	1
3	Completed	Treatment	Osteoarthritis of the Knees	1
3	Completed	Treatment	Smear Positive Pulmonary Tuberculosis	1
3	Completed	Treatment	Type 2 Diabetes Mellitus	1
3	Completed	Treatment	Bone destruction	1
3	Recruiting	Prevention	Cancers / Cardiovascular Disease (CVD) / Fracture Bone	1
3	Recruiting	Prevention	Disseminated Sclerosis	1
3	Recruiting	Treatment	Chronic Rhinosinusitis With Nasal Polyps	1
3	Recruiting	Treatment	Fracture of Neck of Femur	1
3	Recruiting	Treatment	Myocardial Infarction (MI)	1
3	Terminated	Treatment	Chronic Hepatitis C Virus (HCV) Infection	1
3	Terminated	Treatment	Coronary Artery Disease / Deficiency, Vitamin D / Hyperglycemia, Postprandial	1
3	Unknown Status	Prevention	Deficiency, Vitamin D / Pneumonia	1
3	Unknown Status	Prevention	Falls / Fracture Bone	1
3	Unknown Status	Treatment	Disseminated Sclerosis	1
3	Unknown Status	Treatment	Non.Alcoholic Fatty Liver Disease	1
3	Unknown Status	Treatment	Tuberculosis	1
3	Withdrawn	Treatment	Minor burns	1
4	Active Not Recruiting	Prevention	Allergies / Wheezing	1
4	Completed	Not Available	Crohn's Disease (CD) / Low Bone Mineral Density	1
4	Completed	Basic Science	Deficiency, Vitamin D	1
4	Completed	Prevention	Allograft Rejection / Obliterative Bronchiolitis / Transplantation, Lung	1
4	Completed	Prevention	BMI >27 kg/m2 / BMI >30 kg/m2 / Insulin Resistance	1
4	Completed	Prevention	Bone destruction / Bone Loss / Epilepsies / Fracture Bone	1
4	Completed	Prevention	Deficiency, Vitamin D	2
4	Completed	Treatment	Asthma Bronchial	1
4	Completed	Treatment	BMI >30 kg/m2	1
4	Completed	Treatment	BMI >30 kg/m2 / Deficiency, Vitamin D	1
4	Completed	Treatment	Calcium Nephrolithiasis / Deficiency, Vitamin D / Disorder of Vitamin D / Idiopathic Hypercalciuria / Urolithiasis	1
4	Completed	Treatment	Chronic Heart Failure (CHF) / Deficiency, Vitamin D	1
4	Completed	Treatment	Chronic Kidney Disease (CKD) / Deficiency, Vitamin D	1
4	Completed	Treatment	Chronic Kidney Disease (CKD) / Hyperparathyroidism, Secondary	2
4	Completed	Treatment	Congestive Heart Failure (CHF)	1
4	Completed	Treatment	Deficiency, Vitamin D	1
4	Completed	Treatment	Deficiency, Vitamin D / Heart Failure, Unspecified	1
4	Completed	Treatment	Bone destruction / Deficiency, Vitamin D / Hypercalcemia / Hypercalciuria / Osteopenia / Parathyroid deficiency	1
4	Completed	Treatment	Hip Fractures	1
4	Completed	Treatment	Hyperparathyroidism, Secondary	1
4	Completed	Treatment	Nutritional Rickets	1
4	Completed	Treatment	Post Menopausal Osteoporosis	1
4	Completed	Treatment	Postmenopausal Osteoporosis (PMO)	2
4	Completed	Treatment	Pruritis	1
4	Completed	Treatment	Bone destruction	2
4	Enrolling by Invitation	Treatment	Gestational Diabetes Mellitus (GDM)	1
4	Enrolling by Invitation	Treatment	Vitamin D2 Supplementation in Vitamin D Insufficiency	1
4	Not Yet Recruiting	Treatment	Anemias / Chronic Kidney Disease (CKD) / CKD / Ergocalciferol / Hepcidin / Iron-Deficiency / Vitamin D	1
4	Not Yet Recruiting	Treatment	Deficiency, Vitamin D / Hip Fractures	1
4	Recruiting	Basic Science	25-Hydroxyvitamin D Concentration / Deficiency, Vitamin D	1
4	Recruiting	Prevention	Eclampsia / Gestational Hypertension / HELLP Syndrome / Superimposed Preeclampsia / Toxemia	1
4	Recruiting	Prevention	Food Allergy	1
4	Recruiting	Treatment	Adynamic Bone Disease / Deficiency, Vitamin D / Hyperparathyroidism, Secondary / Renal Disease Bone / Renal Disease, End Stage / Restless Leg Disorder	1
4	Recruiting	Treatment	Infertilities	1
4	Recruiting	Treatment	Myopathic Symptoms	1
4	Recruiting	Treatment	Postoperative pain	1
4	Terminated	Treatment	Chronic Hepatitis C Infection / Flaviviridae Infections / Hepatitis C, Chronic / RNA Virus Infections	1
4	Terminated	Treatment	Crohn's Disease (CD) / Deficiency, Vitamin D	1
4	Terminated	Treatment	Deficiency, Vitamin D / Renal Failure Chronic Requiring Hemodialysis	1
4	Unknown Status	Basic Science	Acute Coronary Syndromes (ACS) / Cytokines	1
4	Unknown Status	Prevention	BMI >30 kg/m2 / Insulin Resistance / Vitamin D25 Insufficiency	1
4	Unknown Status	Prevention	Coronary Artery Calcifications / Kidney Diseases	1
4	Unknown Status	Prevention	Crohn's Disease (CD)	1
4	Unknown Status	Treatment	Acute Lower Respiratory Tract Infection / Bronchiolitis / Pneumonia	1
4	Unknown Status	Treatment	BMI >30 kg/m2 / Deficiency, Vitamin D / Hyperparathyroidism, Secondary	1
4	Unknown Status	Treatment	Bone Mineralization Defect	1
4	Unknown Status	Treatment	Chronic Pain Syndrome / Deficiency, Vitamin D / Inflammatory Responses	1
4	Unknown Status	Treatment	Deficiency, Vitamin D / Diabetes	1
4	Unknown Status	Treatment	Deficiency, Vitamin D / Malnutrition	1
4	Unknown Status	Treatment	Disseminated Sclerosis	1
4	Unknown Status	Treatment	Metabolic Syndromes	1
4	Unknown Status	Treatment	Persistent Asthma	1
Not Available	Active Not Recruiting	Treatment	Deficiency, Vitamin D	1
Not Available	Completed	Not Available	Asthma Bronchial / Deficiency, Vitamin D	1
Not Available	Completed	Not Available	Cardiovascular Disease (CVD)	1
Not Available	Completed	Not Available	Diabetes, Diabetes Mellitus Type 1	1
Not Available	Completed	Not Available	HMG COA Reductase Inhibitor Adverse Reaction	1
Not Available	Completed	Not Available	Tuberculosis	1
Not Available	Completed	Not Available	Williams Syndrome	1
Not Available	Completed	Basic Science	Blood Pressures / BMI >27 kg/m2 / BMI >30 kg/m2 / Endothelial Function / Renal Function	1
Not Available	Completed	Other	Type 2 Diabetes Mellitus	1
Not Available	Completed	Prevention	BMI >30 kg/m2 / Diabetes Mellitus, Non-Insulin-Dependent	1
Not Available	Completed	Prevention	Deficiency, Vitamin D	1
Not Available	Completed	Prevention	Diabetes Mellitus, Non-Insulin-Dependent	1
Not Available	Completed	Prevention	End Stage Renal Disease (ESRD)	1
Not Available	Completed	Prevention	Malignant Melanoma of Skin	1
Not Available	Completed	Prevention	Pre-Diabetic	1
Not Available	Completed	Prevention	Risperidone-induced Hyperprolactinemia	1
Not Available	Completed	Prevention	Sarcopenia	1
Not Available	Completed	Supportive Care	Diabetic Neuropathies	1
Not Available	Completed	Supportive Care	Tuberculosis, Pulmonary	1
Not Available	Completed	Treatment	BMI >30 kg/m2	1
Not Available	Completed	Treatment	BMI >30 kg/m2 / Deficiency, Vitamin D / Psychosis / Schizoaffective Disorders / Schizophrenic Disorders	1
Not Available	Completed	Treatment	Back Pain / Hypovitaminosis D	1
Not Available	Completed	Treatment	Coronary Artery Disease / Deficiency, Vitamin D / Endothelial Dysfunction / Inflammatory Reaction	1
Not Available	Completed	Treatment	Cystic Fibrosis (CF)	1
Not Available	Completed	Treatment	Deficiency of Vitamin D3 / Gingival and Periodontal Disease / Pregnancy	1
Not Available	Completed	Treatment	Deficiency, Vitamin D	5
Not Available	Completed	Treatment	Deficiency, Vitamin D / End-Stage Renal Disease (ESRD)	1
Not Available	Completed	Treatment	Deficiency, Vitamin D / Healthy Volunteers	1
Not Available	Completed	Treatment	Bone destruction / Deficiency, Vitamin D	1
Not Available	Completed	Treatment	Diabetes	1
Not Available	Completed	Treatment	HIV Seropositive	1
Not Available	Completed	Treatment	Heart Failure, Unspecified	1
Not Available	Completed	Treatment	Psoriasis Vulgaris	1
Not Available	Completed	Treatment	Systemic Lupus Erythematosus (SLE)	1
Not Available	Completed	Treatment	Transplant Bone Disease	1
Not Available	Completed	Treatment	Moderate, refractory Atopic dermatitis	1
Not Available	Not Yet Recruiting	Prevention	Transient Hypercalciuria	1
Not Available	Recruiting	Prevention	Bone Density	1
Not Available	Recruiting	Supportive Care	Hyperparathyroidism, Secondary	1
Not Available	Recruiting	Treatment	BMI >30 kg/m2	1
Not Available	Recruiting	Treatment	Cardiovascular Disease (CVD) / Deficiency, Vitamin D / Hypertensive / Insulin Resistance / Type 2 Diabetes Mellitus	1
Not Available	Recruiting	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	1
Not Available	Recruiting	Treatment	Deficiency, Vitamin D	2
Not Available	Recruiting	Treatment	Liver Diseases	1
Not Available	Terminated	Not Available	Fractures, Bone / Kidney Diseases / Muscle Weakness / Pain	1
Not Available	Terminated	Treatment	Deficiency, Vitamin D / Moderate, refractory Atopic dermatitis	1
Not Available	Terminated	Treatment	Muscle Cramps	1
Not Available	Unknown Status	Not Available	Chronic Hepatitis C Virus (HCV) Infection	1
Not Available	Unknown Status	Treatment	Chronic Kidney Disease (CKD) / Deficiency, Vitamin D	1
Not Available	Unknown Status	Treatment	Chronic Musculoskeletal Pain / Vitamin D Supplementation	1
Not Available	Unknown Status	Treatment	Chronic Rhinosinusitis	1
Not Available	Unknown Status	Treatment	Deficiency, Vitamin D	1
Not Available	Unknown Status	Treatment	Deficiency, Vitamin D / Rheumatoid Arthritis	1
Not Available	Unknown Status	Treatment	Glucose tolerance impaired / Insulin Resistance	1
Not Available	Unknown Status	Treatment	Impaired Renal Function	1
Not Available	Unknown Status	Treatment	Prostatic Neoplasms	1
Not Available	Withdrawn	Prevention	Hypocalcemia	1
Not Available	Withdrawn	Treatment	Chronic Kidney Disease (CKD) / Deficiency, Vitamin D	1
Not Available	Withdrawn	Treatment	HMG COA Reductase Inhibitor Adverse Reaction	1
Not Available	Withdrawn	Treatment	Hypertensive	1

Pharmacoeconomics

Manufacturers

Eli lilly and co
Sanofi aventis us llc
Orit laboratories llc
Sigmapharm laboratories llc
Strides arcolab ltd
Sun pharmaceutical industries inc
Banner pharmacaps inc
Chase chemical co lp
Everylife
Impax laboratories inc
Lannett co inc
Vitarine pharmaceuticals inc
West ward pharmaceutical corp

Packagers

Dosage forms

Form	Route	Strength
Solution / drops	Oral
Capsule	Oral
Tablet	Oral
Capsule, liquid filled	Oral	1.25 mg/1
Capsule	Oral	1.25 mg/1
Tablet, effervescent	Oral
Injection, powder, lyophilized, for solution	Intravenous
Syrup	Oral
Capsule	Oral	50000 unit
Capsule	Oral	1.25 1/1
Liquid	Oral

Prices

Unit description	Cost	Unit
Ergocalciferol powder	234.4USD	g
Doral 15 mg tablet	3.41USD	tablet
Doral 7.5 mg tablet	3.37USD	tablet
Drisdol 50000 unit capsule	2.34USD	capsule
Drisdol 8288 unit/ml Liquid	0.48USD	ml
Vitamin d 400 unit softgel	0.04USD	softgel capsule
Longs vitamin d 400 unit tablet	0.03USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	116.5 °C	PhysProp
water solubility	50 mg/L	TOMLIN,C (1994)
logP	7.3	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.000433 mg/mL	ALOGPS
logP	7.59	ALOGPS
logP	7.05	ChemAxon
logS	-6	ALOGPS
pKa (Strongest Acidic)	18.38	ChemAxon
pKa (Strongest Basic)	-1.3	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	1	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	20.23 Å²	ChemAxon
Rotatable Bond Count	5	ChemAxon
Refractivity	128.89 m³·mol^-1	ChemAxon
Polarizability	50.73 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.9428
Caco-2 permeable	+	0.8323
P-glycoprotein substrate	Substrate	0.6628
P-glycoprotein inhibitor I	Inhibitor	0.7614
P-glycoprotein inhibitor II	Non-inhibitor	0.8391
Renal organic cation transporter	Non-inhibitor	0.796
CYP450 2C9 substrate	Non-substrate	0.8432
CYP450 2D6 substrate	Non-substrate	0.9003
CYP450 3A4 substrate	Substrate	0.7362
CYP450 1A2 substrate	Non-inhibitor	0.9046
CYP450 2C9 inhibitor	Non-inhibitor	0.8924
CYP450 2D6 inhibitor	Non-inhibitor	0.9519
CYP450 2C19 inhibitor	Non-inhibitor	0.8784
CYP450 3A4 inhibitor	Non-inhibitor	0.8142
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.8163
Ames test	Non AMES toxic	0.9401
Carcinogenicity	Non-carcinogens	0.9169
Biodegradation	Not ready biodegradable	0.9742
Rat acute toxicity	3.6931 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.8502
hERG inhibition (predictor II)	Non-inhibitor	0.7513

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Download (9.78 KB)

Spectra

Spectrum Type	Description	Splash Key
GC-MS	GC-MS Spectrum - GC-MS (1 TMS)	splash10-003u-3911000000-dba9e396497310b31715	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)	splash10-0002-0129000000-77bd32807ec8ea97183b	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)	splash10-0601-5902000000-ae4a4363ac10f9f0feb7	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)	splash10-05mo-9800000000-1ea9f4fa17117a9e6515	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Positive	splash10-01ot-9801000000-17d2120d47f9c718ea95	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - ESI-ITFT , positive	splash10-01ot-9801000000-c10341d61ee2d6369219	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available
1D NMR	1H NMR Spectrum	Not Available
2D NMR	[1H,13C] 2D NMR Spectrum	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as vitamin d and derivatives. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.

Kingdom

Organic compounds

Super Class

Lipids and lipid-like molecules

Class

Steroids and steroid derivatives

Sub Class

Vitamin D and derivatives

Direct Parent

Vitamin D and derivatives

Alternative Parents

Triterpenoids / Secondary alcohols / Cyclic alcohols and derivatives / Hydrocarbon derivatives

Substituents

Triterpenoid / Cyclic alcohol / Secondary alcohol / Organic oxygen compound / Hydrocarbon derivative / Organooxygen compound / Alcohol / Aliphatic homopolycyclic compound

Molecular Framework

Aliphatic homopolycyclic compounds

External Descriptors

hydroxy seco-steroid, seco-ergostane, vitamin D (CHEBI:28934 ) / Vitamin D2 and derivatives, Fat-soluble vitamins (C05441 ) / Vitamin D2 and derivatives (LMST03010000 )

Targets

Details

1. Vitamin D3 receptor

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: agonist

General Function:: Zinc ion binding
Specific Function:: Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Recruited to promoters via its interaction with BAZ1B/WSTF which mediates the interaction with acetylated histones, an essential step for VDR-promoter association. Plays a central role in calcium homeostasis.
Gene Name:: VDR
Uniprot ID:: P11473
Uniprot Name:: Vitamin D3 receptor
Molecular Weight:: 48288.64 Da

References

Carvallo L, Henriquez B, Olate J, van Wijnen AJ, Lian JB, Stein GS, Onate S, Stein JL, Montecino M: The 1alpha,25-dihydroxy Vitamin D3 receptor preferentially recruits the coactivator SRC-1 during up-regulation of the osteocalcin gene. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):420-4. Epub 2007 Jan 10. [PubMed:17218095 ]
Liu W, Tretiakova M, Kong J, Turkyilmaz M, Li YC, Krausz T: Expression of vitamin D3 receptor in kidney tumors. Hum Pathol. 2006 Oct;37(10):1268-78. Epub 2006 Jul 27. [PubMed:16949927 ]
Ewing AK, Attner M, Chakravarti D: Novel regulatory role for human Acf1 in transcriptional repression of vitamin D3 receptor-regulated genes. Mol Endocrinol. 2007 Aug;21(8):1791-806. Epub 2007 May 22. [PubMed:17519354 ]
Gallagher JC, Sai AJ: Vitamin D insufficiency, deficiency, and bone health. J Clin Endocrinol Metab. 2010 Jun;95(6):2630-3. doi: 10.1210/jc.2010-0918. [PubMed:20525913 ]
Straube S, Derry S, Moore RA, McQuay HJ: Vitamin D for the treatment of chronic painful conditions in adults. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007771. doi: 10.1002/14651858.CD007771.pub2. [PubMed:20091647 ]
Jurutka PW, Bartik L, Whitfield GK, Mathern DR, Barthel TK, Gurevich M, Hsieh JC, Kaczmarska M, Haussler CA, Haussler MR: Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands. J Bone Miner Res. 2007 Dec;22 Suppl 2:V2-10. doi: 10.1359/jbmr.07s216. [PubMed:18290715 ]
Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E: Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate. 2007 Jun 15;67(9):911-23. [PubMed:17440943 ]
Marks HD, Fleet JC, Peleg S: Transgenic expression of the human Vitamin D receptor (hVDR) in the duodenum of VDR-null mice attenuates the age-dependent decline in calcium absorption. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):513-6. Epub 2007 Jan 5. [PubMed:17207992 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Details

1. 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Oxidoreductase activity
Specific Function:: Has a role in maintaining calcium homeostasis. Catalyzes the NADPH-dependent 24-hydroxylation of calcidiol (25-hydroxyvitamin D(3)) and calcitriol (1-alpha,25-dihydroxyvitamin D(3)). The enzyme can perform up to 6 rounds of hydroxylation of calcitriol leading to calcitroic acid. It also shows 23-hydroxylating activity leading to 1-alpha,25-dihydroxyvitamin D(3)-26,23-lactone as end product.
Gene Name:: CYP24A1
Uniprot ID:: Q07973
Uniprot Name:: 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial
Molecular Weight:: 58874.695 Da

References

Masuda S, Strugnell SA, Knutson JC, St-Arnaud R, Jones G: Evidence for the activation of 1alpha-hydroxyvitamin D2 by 25-hydroxyvitamin D-24-hydroxylase: delineation of pathways involving 1alpha,24-dihydroxyvitamin D2 and 1alpha,25-dihydroxyvitamin D2. Biochim Biophys Acta. 2006 Feb;1761(2):221-34. Epub 2006 Feb 2. [PubMed:16516540 ]
Sakaki T, Kagawa N, Yamamoto K, Inouye K: Metabolism of vitamin D3 by cytochromes P450. Front Biosci. 2005 Jan 1;10:119-34. Print 2005 Jan 1. [PubMed:15574355 ]
Abe D, Sakaki T, Kusudo T, Kittaka A, Saito N, Suhara Y, Fujishima T, Takayama H, Hamamoto H, Kamakura M, Ohta M, Inouye K: Metabolism of 2 alpha-propoxy-1 alpha,25-dihydroxyvitamin D3 and 2 alpha-(3-hydroxypropoxy)-1 alpha,25-dihydroxyvitamin D3 by human CYP27A1 and CYP24A1. Drug Metab Dispos. 2005 Jun;33(6):778-84. Epub 2005 Mar 11. [PubMed:15764712 ]
Sakaki T: [Recent studies on vitamin D metabolizing enzymes]. Clin Calcium. 2006 Jul;16(7):1129-35. [PubMed:16816472 ]
Inouye K, Sakaki T: Enzymatic studies on the key enzymes of vitamin D metabolism; 1 alpha-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24). Biotechnol Annu Rev. 2001;7:179-94. [PubMed:11686044 ]

Details

2. 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Iron ion binding
Specific Function:: Catalyzes the conversion of 25-hydroxyvitamin D3 (25(OH)D) to 1-alpha,25-dihydroxyvitamin D3 (1,25(OH)2D) plays an important role in normal bone growth, calcium metabolism, and tissue differentiation.
Gene Name:: CYP27B1
Uniprot ID:: O15528
Uniprot Name:: 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial
Molecular Weight:: 56503.475 Da

References

Turunen MM, Dunlop TW, Carlberg C, Vaisanen S: Selective use of multiple vitamin D response elements underlies the 1 alpha,25-dihydroxyvitamin D3-mediated negative regulation of the human CYP27B1 gene. Nucleic Acids Res. 2007;35(8):2734-47. Epub 2007 Apr 10. [PubMed:17426122 ]
Gallagher JC, Sai AJ: Vitamin D insufficiency, deficiency, and bone health. J Clin Endocrinol Metab. 2010 Jun;95(6):2630-3. doi: 10.1210/jc.2010-0918. [PubMed:20525913 ]
Sakaki T, Kagawa N, Yamamoto K, Inouye K: Metabolism of vitamin D3 by cytochromes P450. Front Biosci. 2005 Jan 1;10:119-34. Print 2005 Jan 1. [PubMed:15574355 ]
Sakaki T: [Recent studies on vitamin D metabolizing enzymes]. Clin Calcium. 2006 Jul;16(7):1129-35. [PubMed:16816472 ]
Inouye K, Sakaki T: Enzymatic studies on the key enzymes of vitamin D metabolism; 1 alpha-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24). Biotechnol Annu Rev. 2001;7:179-94. [PubMed:11686044 ]

Details

3. Sterol 26-hydroxylase, mitochondrial

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Vitamin d3 25-hydroxylase activity
Specific Function:: Catalyzes the first step in the oxidation of the side chain of sterol intermediates; the 27-hydroxylation of 5-beta-cholestane-3-alpha,7-alpha,12-alpha-triol. Has also a vitamin D3-25-hydroxylase activity.
Gene Name:: CYP27A1
Uniprot ID:: Q02318
Uniprot Name:: Sterol 26-hydroxylase, mitochondrial
Molecular Weight:: 60234.28 Da

References

Binkley N, Ramamurthy R, Krueger D: Low vitamin D status: definition, prevalence, consequences, and correction. Endocrinol Metab Clin North Am. 2010 Jun;39(2):287-301, table of contents. doi: 10.1016/j.ecl.2010.02.008. [PubMed:20511052 ]
Masuda S, Strugnell SA, Knutson JC, St-Arnaud R, Jones G: Evidence for the activation of 1alpha-hydroxyvitamin D2 by 25-hydroxyvitamin D-24-hydroxylase: delineation of pathways involving 1alpha,24-dihydroxyvitamin D2 and 1alpha,25-dihydroxyvitamin D2. Biochim Biophys Acta. 2006 Feb;1761(2):221-34. Epub 2006 Feb 2. [PubMed:16516540 ]
Sakaki T, Kagawa N, Yamamoto K, Inouye K: Metabolism of vitamin D3 by cytochromes P450. Front Biosci. 2005 Jan 1;10:119-34. Print 2005 Jan 1. [PubMed:15574355 ]
Abe D, Sakaki T, Kusudo T, Kittaka A, Saito N, Suhara Y, Fujishima T, Takayama H, Hamamoto H, Kamakura M, Ohta M, Inouye K: Metabolism of 2 alpha-propoxy-1 alpha,25-dihydroxyvitamin D3 and 2 alpha-(3-hydroxypropoxy)-1 alpha,25-dihydroxyvitamin D3 by human CYP27A1 and CYP24A1. Drug Metab Dispos. 2005 Jun;33(6):778-84. Epub 2005 Mar 11. [PubMed:15764712 ]
Sakaki T: [Recent studies on vitamin D metabolizing enzymes]. Clin Calcium. 2006 Jul;16(7):1129-35. [PubMed:16816472 ]

Details

4. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Vitamin d3 25-hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:: CYP3A4
Uniprot ID:: P08684
Uniprot Name:: Cytochrome P450 3A4
Molecular Weight:: 57342.67 Da

References

Binkley N, Ramamurthy R, Krueger D: Low vitamin D status: definition, prevalence, consequences, and correction. Endocrinol Metab Clin North Am. 2010 Jun;39(2):287-301, table of contents. doi: 10.1016/j.ecl.2010.02.008. [PubMed:20511052 ]

Details

5. Vitamin D 25-hydroxylase

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Vitamin d3 25-hydroxylase activity
Specific Function:: Has a D-25-hydroxylase activity on both forms of vitamin D, vitamin D(2) and D(3).
Gene Name:: CYP2R1
Uniprot ID:: Q6VVX0
Uniprot Name:: Vitamin D 25-hydroxylase
Molecular Weight:: 57358.82 Da

References

Ramos-Lopez E, Bruck P, Jansen T, Pfeilschifter JM, Radeke HH, Badenhoop K: CYP2R1-, CYP27B1- and CYP24-mRNA expression in German type 1 diabetes patients. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):807-10. Epub 2007 Jan 16. [PubMed:17223345 ]
Ramos-Lopez E, Bruck P, Jansen T, Herwig J, Badenhoop K: CYP2R1 (vitamin D 25-hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans. Diabetes Metab Res Rev. 2007 Nov;23(8):631-6. [PubMed:17607662 ]
Masuda S, Strugnell SA, Knutson JC, St-Arnaud R, Jones G: Evidence for the activation of 1alpha-hydroxyvitamin D2 by 25-hydroxyvitamin D-24-hydroxylase: delineation of pathways involving 1alpha,24-dihydroxyvitamin D2 and 1alpha,25-dihydroxyvitamin D2. Biochim Biophys Acta. 2006 Feb;1761(2):221-34. Epub 2006 Feb 2. [PubMed:16516540 ]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2017 16:20

Structure for DB00153 (Ergocalciferol)

Targets

References

Enzymes

References

References

References

References

References